logo

Preparation and preliminary biological evaluation of 99mTc-ANMdU

RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE

Preparation and preliminary biological evaluation of 99mTc-ANMdU

LU Chunxiong
JIANG Quanfu
YU Huixin
WANG Songpei
Li Xiaomin
WANG Zhengwu
Nuclear Science and TechniquesVol.21, No.2pp.106-109Published in print 20 Apr 2010
33100

Technetium-99m-labeled-5-{2-sulfanylethyl-[2-(2-sulfanylethylamino)acetyl]amino}-methyl-2′-deoxy- uridine (99mTc-ANMdU) was reported. The precursor ANMdU was synthesized by six-step reactions and all intermediates were verified with MS and 1HNMR. Using SnCl2 as reducing agent, a labeling reaction was carried out at 100°C for 30 min. The radiochemical purity of the 99mTc-ANMdU was 96.68%. Partition coefficients were 0.92 and 0.70 at pH 7.0 and 7.4 of the phosphate buffer saline, respectively. Biodistribution of 99mTc-ANMdU in normal mice showed that the initial uptake of 99mTc-ANMdU in vivo and the clearance was rapid.

Synthesis99mTc-ANMdUBiodistributionA thymidine analog
References
[1] Shields A F, Grierson J R, Dohmen B M, et al. Nat Med, 1998, 4(11): 1334-1336.
[2] Kubota R, Yamada S, Kubota K, et al. J Nucl Med, 1992, 33(11): 1972-1980.
[3] Lu L, Samuelsson L, Bergstrfm M, et al. J Nucl Med, 2002, 43(12): 1688-1698.
[4] Shields A F, J Nucl Med, 2003, 44(9): 1432-1434.
[5] Barthel H, Perumal M, Latigo J, et al. Eur J Nucl Med Mol Imaging, 2005, 32(3): 257-263.
[6] Barthel H, Cleij M C, Collingridge, D R, et al. Cancer Res, 2003, 63(13): 3791-3798.
[7] Chen W, Cloughesy T, Kamdar N, et al. J Nucl Med, 2005, 46(6): 945-952.
[8] Sun H, Sloan A, Mangner T J, et al. Eur J Nucl Med Mol Imaging, 2005, 32(1): 15-22.
[9] Zhang Y, Dai X, Kallmes D F, et al. Tetrahedron Lett, 2004, 45(47): 8673-8676.
[10] Teng B, Bai Y, Chang Y, et al. Bioorgan Med Chem Lett, 2007, 17(12): 3440-3444.
[11] Celen S, Groot T, Balzarini J, et al. Nucl Med Bio, 2007, 34(3): 283-291.
[12] Lu C, Wang Z, Jiang Q, et al. J Isoto, 2008, 21(3): 145-149. (in Chinese)